FILTER

Refine your search with the following facets to narrow down your results.

10 Current news of Fresenius

Merck Divests Biosimilars Business to Fresenius

25-Apr-2017 - Merck announced the divestment of its Biosimilars business to Fresenius. The decision to divest Biosimilars is aligned with Merck’s strategy for its Healthcare business sector to focus on its pipeline of innovative medicines. According to the terms agreed for the transaction, Merck will receive ...

biosimilars Fresenius Merck

Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab

31-Jan-2011 - Swedish Orphan Biovitrum announced a Removab® distribution agreement with Fresenius Biotech. Under the agreement Swedish Orphan Biovitrum (Sobi) will distribute Removab® exclusively in 15 European countries over 7 years. Removab® was granted marketing authorization by the European Commission in ...

Fresenius

Trifunctional antibody Removab from Fresenius Biotech awarded Galenus von Pergamon Prize for drug innovation

29-Oct-2010 - The trifunctional antibody Removab® (Catumaxomab) from Fresenius Biotech was awarded this year’s Galenus von Pergamon Prize in the “Specialist Care” category. The jury acknowledged Removab®’s new therapeutic mechanism and medical relevance for the treatment of malignant ascites. The Galenus von ...

adhesion antibodies dendritic cells +6

Fresenius Kabi and Bayer Schering Pharma extend collaboration regarding HESylation Technology

15-Jan-2010 - Fresenius Kabi Deutschland GmbH and Bayer Schering Pharma AG have extended their collaboration in the field of HESylation® Technology. The companies started their cooperation in May 2009 and now have entered into the next phase of development. The extension of the collaboration is combined with a ...

Bayer Schering Fresenius hydroxyethyl starch +2

Fresenius Kabi and Octapharma Group enter into an Exclusive Agreement for a HESylated recombinant protein

30-Oct-2009 - Fresenius Kabi and Octapharma Group have signed a License, Development and Supply Agreement regarding the use of Fresenius Kabi’s HESylation® Technology to develop a HESylated recombinant protein. Under the agreement, Fresenius Kabi will license its proprietary HESylation® Technology to ...

Fresenius hydroxyethyl starch milestone payments +2

BioNTech AG acquires EUFETS AG

09-Jun-2009 - BioNTech AG announced the acquisition of all shares of EUFETS AG from Fresenius Biotech GmbH (Munich, Germany). EUFETS, formerly a fully owned subsidiary of Fresenius Biotech GmbH, is a specialist in GMP and GLP services for innovative biopharmaceutical approaches. Under the new owner, EUFETS ...

BioNTech Fresenius Germany +4

Fresenius Kabi and Bayer Schering Pharma enter into a Research, Development and License Agreement

04-Jun-2009 - Fresenius Kabi Deutschland GmbH and Bayer Schering Pharma AG have signed a Research, Development and License Agreement regarding the use of Fresenius Kabi Deutschland GmbH’s HESylation® Technology in a limited field of use. Under the agreement, Fresenius Kabi will license its proprietary ...

Bayer Schering Fresenius hydroxyethyl starch +3

Removab Approval: Proof-of-Concept for Technology Transfer in Germany

27-Apr-2009 - The European Commission has granted approval for the trifunctional anti-cancer antibody Removab®. It is the first approved therapeutic antibody originating from a German research institution that has been brought to market by its own spin-out together with a pharma partner. "This success story ...

antibodies Ascenion flow +5

Fresenius to acquire US drug-maker APP Pharmaceuticals in US$3.7 billion deal

08-Jul-2008 - Fresenius SE said Monday that it reached a deal to buy U.S. generic drug maker APP Pharmaceuticals in a US$3.7 billion deal that will give the German company more opportunities in the North American intravenously administered drug market. Bad Homburg-based Fresenius SE will pay US$23 in cash for ...

Fresenius oncology

Enzon Returns Rights To Transplantation Product To Fresenius Biotech

10-Jan-2006 - Enzon Pharmaceuticals, Inc. announced that it is returning its rights to ATG-Fresenius S to Fresenius Biotech GmbH, a subsidiary of the health care company Fresenius AG. ATG-Fresenius S is a polyclonal antibody preparation used for T-lymphocyte suppression to prevent organ graft rejection in ...

clinical trials Fresenius